Nanovesicles from eCSF increase IGF-mTORC1 activity in eNSCs <i>in vitro</i>.

Abstract

<p>(<b>A</b>) Control and nanovesicle-treated eNSCs <i>in vitro</i> immunostained for phospho-(p) S6 (red), and nestin (green), and counterstained for the nuclear marker DAPI (blue). (<b>B</b>) Zoom of the image in the white square in (A). (<b>C</b>) Number of phospho-S6-positive cells relative to total with or without nanovesicle application (N = 3 and 4 cultures, 2–4 litters for nanovesicle extraction). Experiments were reproduced in the presence of vehicle (DMSO) or 100 nM rapamycin (N = 3 each). (<b>D</b>) Relative total cell number (N = 3 each). (<b>E</b>) Percentage of nestin-positive eNSCs (N = 3 each). (<b>F</b>) Percentage of Ki67- and nestin-positive eNSCs (N = 9 control and 3 with nanovesicle). *: p<0.05, **: p<0.01, ***: p<0.001 with Student's t test or one way ANOVA. Scale bars: 200 µm (A and B). Error bars: SEM.</p